The p53 Pathway in Glioblastoma
Tóm tắt
The tumor suppressor and transcription factor p53 plays critical roles in tumor prevention by orchestrating a wide variety of cellular responses, including damaged cell apoptosis, maintenance of genomic stability, inhibition of angiogenesis, and regulation of cell metabolism and tumor microenvironment. TP53 is one of the most commonly deregulated genes in cancer. The p53-ARF-MDM2 pathway is deregulated in 84% of glioblastoma (GBM) patients and 94% of GBM cell lines. Deregulated p53 pathway components have been implicated in GBM cell invasion, migration, proliferation, evasion of apoptosis, and cancer cell stemness. These pathway components are also regulated by various microRNAs and long non-coding RNAs. TP53 mutations in GBM are mostly point mutations that lead to a high expression of a gain of function (GOF) oncogenic variants of the p53 protein. These relatively understudied GOF p53 mutants promote GBM malignancy, possibly by acting as transcription factors on a set of genes other than those regulated by wild type p53. Their expression correlates with worse prognosis, highlighting their potential importance as markers and targets for GBM therapy. Understanding mutant p53 functions led to the development of novel approaches to restore p53 activity or promote mutant p53 degradation for future GBM therapies.
Từ khóa
Tài liệu tham khảo
Jeffrey, 1995, Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms, Science, 267, 1498, 10.1126/science.7878469
Rajagopalan, 2011, Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53, Nucleic Acids Res., 39, 2294, 10.1093/nar/gkq800
Wei, 2006, A global map of p53 transcription-factor binding sites in the human genome, Cell, 124, 207, 10.1016/j.cell.2005.10.043
Wade, 2013, MDM2, MDMX and p53 in oncogenesis and cancer therapy, Nat. Rev. Cancer, 13, 83, 10.1038/nrc3430
Bieging, 2014, Unravelling mechanisms of p53-mediated tumour suppression, Nat. Rev. Cancer, 14, 359, 10.1038/nrc3711
Schapira, A.H.V. (2007). Neurology and Clinical Neuroscience, Mosby Elsevier.
Gallego, 2015, Nonsurgical treatment of recurrent glioblastoma, Curr. Oncol., 22, e273, 10.3747/co.22.2436
Louis, 2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary, Acta Neuropathol., 131, 803, 10.1007/s00401-016-1545-1
Kloosterhof, 2011, Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?, Lancet Oncol., 12, 83, 10.1016/S1470-2045(10)70053-X
Brennan, 2013, The somatic genomic landscape of glioblastoma, Cell, 155, 462, 10.1016/j.cell.2013.09.034
Verhaak, 2010, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell, 17, 98, 10.1016/j.ccr.2009.12.020
Nandeesh, 2018, Recurrent Glioblastomas Exhibit Higher Expression of Biomarkers with Stem-like Properties, J. Neurosci. Rural Pract., 9, 86, 10.4103/jnrp.jnrp_417_17
Stark, 2003, p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme, J. Neurol. Neurosurg. Psychiatry, 74, 779, 10.1136/jnnp.74.6.779
Wiewrodt, 2008, MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome, Int. J. Cancer, 122, 1391, 10.1002/ijc.23219
Rivlin, 2011, Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis, Genes Cancer, 2, 466, 10.1177/1947601911408889
Ishii, 1999, Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines, Brain Pathol., 9, 469, 10.1111/j.1750-3639.1999.tb00536.x
Wang, 2001, Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ, Biochem. Biophys. Res. Commun., 287, 173, 10.1006/bbrc.2001.5565
Cerami, 2012, The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data, Cancer Discov., 2, 401, 10.1158/2159-8290.CD-12-0095
Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal., 6, pl1, 10.1126/scisignal.2004088
Leroy, 2013, The TP53 website: An integrative resource centre for the TP53 mutation database and TP53 mutant analysis, Nucleic Acids Res., 41, D962, 10.1093/nar/gks1033
Tsuchiya, 2000, Functional restoration of tumor suppressor p53 alters susceptibility of glioblastoma cells to irradiation—Analysis using a cell line containing a temperature-sensitive mutant, Hokkaido Igaku Zasshi, 75, 265
Lin, 2005, p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression, Nat. Cell Biol., 7, 165, 10.1038/ncb1211
England, 2013, Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme, Tumour Biol., 34, 2063, 10.1007/s13277-013-0871-3
Zheng, 2008, p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation, Nature, 455, 1129, 10.1038/nature07443
Krex, 2003, Genetic analysis of a multifocal glioblastoma multiforme: A suitable tool to gain new aspects in glioma development, Neurosurgery, 53, 1377, 10.1227/01.NEU.0000093426.29236.86
Djuzenova, 2015, Actin cytoskeleton organization, cell surface modification and invasion rate of 5 glioblastoma cell lines differing in PTEN and p53 status, Exp. Cell Res., 330, 346, 10.1016/j.yexcr.2014.08.013
Park, 2006, Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin, Int. J. Oncol., 28, 119
Petitjean, 2007, TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes, Oncogene, 26, 2157, 10.1038/sj.onc.1210302
Rich, 2005, Gene expression profiling and genetic markers in glioblastoma survival, Cancer Res., 65, 4051, 10.1158/0008-5472.CAN-04-3936
Kraus, 2000, Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme, J. Neurooncol., 48, 89, 10.1023/A:1006402614838
Zadeh, 2007, Frequent homozygous deletion of p16/CDKN2A gene in malignant gliomas of Iranian patients, Pak. J. Biol. Sci., 10, 4246, 10.3923/pjbs.2007.4246.4250
Zerrouqi, 2012, P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3, J. Clin. Investig., 122, 1283, 10.1172/JCI38596
Rickert, 2009, Glioblastoma with adipocyte-like tumor cell differentiation—Histological and molecular features of a rare differentiation pattern, Brain Pathol., 19, 431, 10.1111/j.1750-3639.2008.00199.x
Ghimenti, 2003, Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets, J. Neurooncol., 61, 95, 10.1023/A:1022127302008
Fulci, 2000, p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma, Oncogene, 19, 3816, 10.1038/sj.onc.1203700
Biernat, 1998, Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas, Pol. J. Pathol., 49, 267
Crespo, 2015, Molecular and Genomic Alterations in Glioblastoma Multiforme, Am. J. Pathol., 185, 1820, 10.1016/j.ajpath.2015.02.023
Nobusawa, 2010, Intratumoral patterns of genomic imbalance in glioblastomas, Brain Pathol., 20, 936, 10.1111/j.1750-3639.2010.00395.x
Rao, 2010, A survey of glioblastoma genomic amplifications and deletions, J. Neurooncol., 96, 169, 10.1007/s11060-009-9959-4
He, 1994, Analysis of glioma cell lines for amplification and overexpression of MDM2, Genes Chromosomes Cancer, 11, 91, 10.1002/gcc.2870110205
Wang, 2017, Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist, J. Neurosurg., 126, 446, 10.3171/2016.1.JNS152513
Rolle, 2015, miRNA Multiplayers in glioma. From bench to bedside, Acta Biochim. Pol., 62, 353, 10.18388/abp.2015_1072
Liu, 2014, Regulatory roles of miRNA in the human neural stem cell transformation to glioma stem cells, J. Cell Biochem., 115, 1368, 10.1002/jcb.24786
Lavorgna, 2016, Long non-coding RNAs as novel therapeutic targets in cancer, Pharmacol. Res., 110, 131, 10.1016/j.phrs.2016.05.018
Ruvkun, 2001, Molecular biology. Glimpses of a tiny RNA world, Science, 294, 797, 10.1126/science.1066315
Lee, 1993, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell, 75, 843, 10.1016/0092-8674(93)90529-Y
Li, 2009, MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes, Cancer Res., 69, 7569, 10.1158/0008-5472.CAN-09-0529
Wu, 2013, MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell apoptosis through p53 and p38MAPK-independent pathways, Br. J. Cancer, 109, 2853, 10.1038/bjc.2013.672
Zhao, 2013, Downregulation of miR-124 promotes the growth and invasiveness of glioblastoma cells involving upregulation of PPP1R13L, Int. J. Mol. Med., 32, 101, 10.3892/ijmm.2013.1365
Li, 2015, Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma, Oncogene, 34, 1619, 10.1038/onc.2014.98
Li, 2012, Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2, Oncotarget, 3, 1653, 10.18632/oncotarget.810
Mattick, 2015, Discovery and annotation of long noncoding RNAs, Nat. Struct. Mol. Biol., 22, 5, 10.1038/nsmb.2942
He, 2017, The lncRNA UCA1 interacts with miR-182 to modulate glioma proliferation and migration by targeting iASPP, Arch. Biochem. Biophys., 623–624, 1, 10.1016/j.abb.2017.01.013
Zhao, 2016, The lncRNA H19 interacts with miR-140 to modulate glioma growth by targeting iASPP, Arch. Biochem. Biophys., 610, 1, 10.1016/j.abb.2016.09.014
Lang, 2004, Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome, Cell, 119, 861, 10.1016/j.cell.2004.11.006
Walker, 1999, Evolutionary conservation and somatic mutation hotspot maps of p53: Correlation with p53 protein structural and functional features, Oncogene, 18, 211, 10.1038/sj.onc.1202298
Cho, 1994, Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations, Science, 265, 346, 10.1126/science.8023157
Galia, 2012, PARP-1 protein expression in glioblastoma multiforme, Eur. J. Histochem., 56, e9, 10.4081/ejh.2012.e9
Harris, 2005, The p53 pathway: Positive and negative feedback loops, Oncogene, 24, 2899, 10.1038/sj.onc.1208615
Lukashchuk, 2007, Ubiquitination and degradation of mutant p53, Mol. Cell Biol., 27, 8284, 10.1128/MCB.00050-07
Zheng, 2013, Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis, Nat. Commun., 4, 2996, 10.1038/ncomms3996
Li, 2011, Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells, Mol. Cancer Res., 9, 577, 10.1158/1541-7786.MCR-10-0534
Muller, 2009, Mutant p53 drives invasion by promoting integrin recycling, Cell, 139, 1327, 10.1016/j.cell.2009.11.026
Blandino, 2012, Mutant p53 protein, master regulator of human malignancies: A report on the Fifth Mutant p53 Workshop, Cell Death Differ., 19, 180, 10.1038/cdd.2011.148
Mizuno, 2012, Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway, Cell, 148, 244, 10.1016/j.cell.2011.12.017
Zhang, 2013, Tumour-associated mutant p53 drives the Warburg effect, Nat. Commun., 4, 2935, 10.1038/ncomms3935
Muller, 2011, p53 and its mutants in tumor cell migration and invasion, J. Cell Biol., 192, 209, 10.1083/jcb.201009059
Yue, 2017, Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy, J. Mol. Biol., 429, 1595, 10.1016/j.jmb.2017.03.030
Strano, 2006, Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation, Cancer Cell, 10, 191, 10.1016/j.ccr.2006.08.013
Dupont, 2009, FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination, Cell, 136, 123, 10.1016/j.cell.2008.10.051
Sampath, 2001, Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1, J. Biol. Chem., 276, 39359, 10.1074/jbc.M103429200
Stambolsky, 2010, Modulation of the vitamin D3 response by cancer-associated mutant p53, Cancer Cell, 17, 273, 10.1016/j.ccr.2009.11.025
Brosh, 2009, When mutants gain new powers: News from the mutant p53 field, Nat. Rev. Cancer, 9, 701, 10.1038/nrc2693
Finlay, 1989, The p53 proto-oncogene can act as a suppressor of transformation, Cell, 57, 1083, 10.1016/0092-8674(89)90045-7
Gaiddon, 2001, A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain, Mol. Cell Biol., 21, 1874, 10.1128/MCB.21.5.1874-1887.2001
Vogiatzi, 2016, Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5, Proc. Natl. Acad. Sci. USA, 113, E8433, 10.1073/pnas.1612711114
Nguyen, 2014, Mutant TP53 posttranslational modifications: Challenges and opportunities, Hum. Mutat., 35, 738, 10.1002/humu.22506
Suh, 2011, Multiple stress signals activate mutant p53 in vivo, Cancer Res., 71, 7168, 10.1158/0008-5472.CAN-11-0459
Nagpal, 2006, Revisiting the role of p53 in primary and secondary glioblastomas, Anticancer Res., 26, 4633
Kraus, 2001, TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme, J. Neurooncol., 52, 263, 10.1023/A:1010684203704
Ohgaki, 2005, Genetic pathways to glioblastomas, Neuropathology, 25, 1, 10.1111/j.1440-1789.2004.00600.x
Watanabe, 1997, Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies, Clin. Cancer Res., 3, 523
Peraud, 2002, Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas, Clin. Cancer Res., 8, 1117
Okamoto, 2004, Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas, Acta Neuropathol., 108, 49, 10.1007/s00401-004-0861-z
Green, 2009, Cytoplasmic functions of the tumour suppressor p53, Nature, 458, 1127, 10.1038/nature07986
Martin, 2012, Integrins and p53 pathways in glioblastoma resistance to temozolomide, Front. Oncol., 2, 157, 10.3389/fonc.2012.00157
Pathania, 2017, H3.3(K27M) Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas, Cancer Cell, 32, 684, 10.1016/j.ccell.2017.09.014
Hesselager, 2003, Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model, Cancer Res., 63, 4305
Zalcenstein, 2003, Mutant p53 gain of function: Repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants, Oncogene, 22, 5667, 10.1038/sj.onc.1206724
Kleber, 2008, Yes and PI3K bind CD95 to signal invasion of glioblastoma, Cancer Cell, 13, 235, 10.1016/j.ccr.2008.02.003
Wisniewski, 2010, Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 activity via NFkappaB-TIMP-2 pathway, Cell Signal., 22, 212, 10.1016/j.cellsig.2009.09.016
Sano, 1999, Differential expression of MMAC/PTEN in glioblastoma multiforme: Relationship to localization and prognosis, Cancer Res., 59, 1820
Vikhanskaya, 2007, Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53, Nucleic. Acids Res., 35, 2093, 10.1093/nar/gkm099
Lin, 2012, R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3beta/PTEN pathway, Neurosci. Lett., 529, 60, 10.1016/j.neulet.2012.09.022
Mendrysa, 2011, p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer, Genes Cancer, 2, 431, 10.1177/1947601911409736
Burness, 2010, The stem cell niche in health and malignancy, Semin. Cancer Biol., 20, 107, 10.1016/j.semcancer.2010.05.006
Flores, 2005, Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family, Cancer Cell, 7, 363, 10.1016/j.ccr.2005.02.019
Moll, 2001, p53, p63 and p73—Solos, alliances and feuds among family members, Biochim. Biophys. Acta, 1552, 47
Palani, 2011, Frequency variations in the methylated pattern of p73/p21 genes and chromosomal aberrations correlating with different grades of glioma among south Indian population, Med. Oncol., 28, S445, 10.1007/s12032-010-9671-4
Ham, S.W., Jeon, H.Y., Jin, X., Kim, E.J., Kim, J.K., Shin, Y.J., Lee, Y., Kim, S.H., Lee, S.Y., and Seo, S. (2018). TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ.
Li, 2008, PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations, Cancer Res., 68, 1723, 10.1158/0008-5472.CAN-07-1963
Huang, 2013, A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy, Neoplasia, 15, 952, 10.1593/neo.13376
Pfister, 2015, Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells, Genes Dev., 29, 1298, 10.1101/gad.263202.115
Brazdova, 2009, Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences, Nucleic Acids Res., 37, 1486, 10.1093/nar/gkn1085
Quante, 2012, Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity, Cell Cycle, 11, 3290, 10.4161/cc.21646
Zhu, 2015, Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth, Nature, 525, 206, 10.1038/nature15251
Joerger, 2008, Structural biology of the tumor suppressor p53, Annu. Rev. Biochem., 77, 557, 10.1146/annurev.biochem.77.060806.091238
Muller, 2014, Mutant p53 in cancer: New functions and therapeutic opportunities, Cancer Cell, 25, 304, 10.1016/j.ccr.2014.01.021
Vu, 2013, Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development, ACS Med. Chem. Lett., 4, 466, 10.1021/ml4000657
Canon, 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents, Mol. Cancer Ther., 14, 649, 10.1158/1535-7163.MCT-14-0710
Her, 2018, Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells, Cell Death Dis., 9, 792, 10.1038/s41419-018-0825-1
Verreault, 2016, Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas, Clin. Cancer Res., 22, 1185, 10.1158/1078-0432.CCR-15-1015
Daniele, 2014, Apoptosis therapy in cancer: The first single-molecule co-activating p53 and the translocator protein in glioblastoma, Sci. Rep., 4, 4749, 10.1038/srep04749
Lehmann, 2012, Targeting mutant p53 in human tumors, J. Clin. Oncol., 30, 3648, 10.1200/JCO.2012.44.0412
Wiman, 2010, Pharmacological reactivation of mutant p53: From protein structure to the cancer patient, Oncogene, 29, 4245, 10.1038/onc.2010.188
Weinmann, 2008, A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis, Cell Death Differ., 15, 718, 10.1038/sj.cdd.4402301
Wischhusen, 2003, CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death, Oncogene, 22, 8233, 10.1038/sj.onc.1207198
Bykov, 2002, Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound, Nat. Med., 8, 282, 10.1038/nm0302-282
Lambert, 2009, PRIMA-1 reactivates mutant p53 by covalent binding to the core domain, Cancer Cell, 15, 376, 10.1016/j.ccr.2009.03.003
Nahi, 2004, Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion, Br. J. Haematol., 127, 285, 10.1111/j.1365-2141.2004.05210.x
Nahi, 2006, PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion, Br. J. Haematol., 132, 230, 10.1111/j.1365-2141.2005.05851.x
Patyka, 2016, Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status, Oncotarget, 7, 60245, 10.18632/oncotarget.11197
Bykov, 2005, PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis, Oncogene, 24, 3484, 10.1038/sj.onc.1208419
Zache, 2008, PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53, Cell Oncol., 30, 411
Lehmann, 2012, Targeting p53 in vivo: A first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer, J. Clin. Oncol., 30, 3633, 10.1200/JCO.2011.40.7783
Duffy, 2017, Mutant p53 as a target for cancer treatment, Eur. J. Cancer, 83, 258, 10.1016/j.ejca.2017.06.023
Aggarwal, 2016, Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth, Cell Death Differ., 23, 1615, 10.1038/cdd.2016.48
Soragni, 2016, A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas, Cancer Cell, 29, 90, 10.1016/j.ccell.2015.12.002
Tal, 2016, Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides, Oncotarget, 7, 11817, 10.18632/oncotarget.7857
Joerger, 2016, The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches, Annu. Rev. Biochem., 85, 375, 10.1146/annurev-biochem-060815-014710
Pal, 2018, Dual HDAC and PI3K inhibition abrogates NFkappaB- and FOXM1-mediated DNA damage response to radiosensitize pediatric high-grade gliomas, Cancer Res., 78, 4007, 10.1158/0008-5472.CAN-17-3691
Staberg, 2017, Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine, Cell Oncol., 40, 21, 10.1007/s13402-016-0301-9
Liffers, 2016, Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition, Target Oncol., 11, 29, 10.1007/s11523-015-0372-y
Singh, 2015, Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma, Neuro Oncol., 17, 1463, 10.1093/neuonc/nov041
Li, 2011, SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis, Cell Death Differ., 18, 1904, 10.1038/cdd.2011.71
Kitange, 2012, Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts, Clin. Cancer Res., 18, 4070, 10.1158/1078-0432.CCR-12-0560
Yang, 2017, SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study, Oncotarget, 8, 3156, 10.18632/oncotarget.13680
Choi, 2017, A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma, Oncotarget, 8, 9123, 10.18632/oncotarget.13265
Rasmussen, 2016, Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma, Mol. Oncol., 10, 751, 10.1016/j.molonc.2015.12.014
Yan, 2013, Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8, Oncogene, 32, 599, 10.1038/onc.2012.81